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missions. Often it is mentioned that in order to obtain unbiased
estimates based on indirect comparisons the distribution of char-
acteristics of the patients included in the different trials needs to
be similar, as well as the study design. By means of directed
acyclic graphs (DAGs), which are often used in epidemiology for
inferences, it is explained that indirect and mixed treatment
comparisons are biased when differences in patient characteris-
tics and trial design do act as an effect modiﬁer of the treatment
effect. Furthermore, the graphs can be used to differentiate
between heterogeneity, selection, and confounding bias. DAGs
for indirect comparisons of RCTs are compared with DAGs for
head-to-head randomized designs and meta-analysis of RCTs.
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OBJECTIVES: Per member per month (PMPM) utilization rates
are commonly reported in the medical literature to compare
differences in costs and other outcomes across various health care
technologies and interventions. A limitation of PMPM estimates
is that a conﬁdence limit around the point estimate is not obvious
or available from standard statistical software. Our objective is
to demonstrate various methods of calculating conﬁdence inter-
vals for PMPM utilization rates. METHODS: Several methods
were used to estimate conﬁdence intervals surrounding PMPM
estimates including Fieller’s method and Monte-Carlo (MC)
simulation. Women with at least one prescription ﬁll for alendr-
onate, risedronate, or ibandronate during 2006 in a large
managed care data set were used as a sample to generate PMPM
estimates and 95% conﬁdence intervals for bisphosphonate drug
cost, all hospitalization cost, hospital days, and number of hos-
pital admissions during the calendar year of 2006. RESULTS:
There were 34,675 women in our sample. The PMPM estimate
of bisphosphonate drug cost was $23.48. The 95% conﬁdence
intervals generated by the Fieller and MC methods were ($23.21,
$23.75) and ($23.45, $23.87), respectively. The PMPM hospi-
talization cost was $242.28: Fieller and MC 95% conﬁdence
intervals were ($221.53, $263.03) and ($227.74, $259.99),
respectively. The PMPM estimate of hospital days was 0.108
days: Fieller and MC 95% conﬁdence intervals were (0.098,
0.118) and (0.100, 0.116), respectively. The PMPM point esti-
mate for number of hospital admissions was 0.0137: Fieller
and MC 95% conﬁdence intervals were (0.0131, 0.0142) and
(0.0133, 0.0142), respectively. CONCLUSION: The Fieller and
MC simulation methods produced similar conﬁdence intervals
for PMPM estimates for each of the outcomes of interest. Use of
these methods would improve the utility of PMPM point esti-
mates in comparing health care technologies.
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Cost-effectiveness acceptability curves (CEACs) plot the prob-
ability that one treatment is more cost-effective than another, as
a function of a societal threshold willingness to pay for addi-
tional units of efﬁcacy (e.g., life-year or QALY gained). OBJEC-
TIVES: To assess the adoption and diffusion rates of CEACs
within the ﬁeld of economic evaluations. METHODS: We used
the Tufts-New England Medical Center registry of 620 published
cost-effectiveness analyses (CEA), presenting an original cost/
QALY ratio from 2002–2005 (http://www.tufts-nemc.org/
cearegistry/). For each CEA we recorded the year of publication,
journal’s name, study origin (country), and a subjective assess-
ment of overall study quality ranging from 1 (low) to 7 (high).
We used univariate analyses (chi-square and t-test), to assess
differences in CEAC use by year of publication, study origin and
quality. We also compared practices in journals publishing a
high-volume (n  10) versus low-volume (n < 10) of CEAs
during the study period. We used multivariable logistic regression
to identify factors predicting CEAC use. RESULTS: Approxi-
mately one ﬁfth (20.2%) of CEAs presented a CEAC. The adop-
tion of CEACs has increased over time from 5.3% (2002) to
30.4% (2005) (p < 0.0001). Studies using CEAC were of higher
quality (4.6  1.0 vs.4.1  0.9; p < 0.0001) and more prevalent
in high-volume journals (30.7% vs. 16.4%; p < 0.0001). CEACs
were more frequently used in UK studies (48.8%) versus studies
from Sweden (24.1%), The Netherlands (17.9%), United States
(11.7%), and Canada (9.1%). Signiﬁcant predictors for using
CEACs were study quality (OR 1.96; 95% CI-1.53–2.51), pub-
lication in a high-volume journal (OR 1.85; 95% CI-1.18–2.89),
and year of publication. CONCLUSIONS: CEACs have been
rapidly adopted, especially among UK-based investigators. If
CEACs turn out to be a useful tool to decision makers, this trend
is encouraging, but means to achieve more rapid deployment
should be identiﬁed.
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OBJECTIVE: To review and critically evaluate published cost-
utility analysis (CUA) research on pharmaceuticals for the
past three decades. METHODS: We examined data from the
Tufts-NEMC Cost-Effectiveness Analysis Registry www.tufts-
nemc.org/cearegistry), which contains detailed information on
over 1100 CUAs and 3000 cost-utility ratios (in $US2005) pub-
lished from 1976–2005. RESULTS: Of 1164 CUAs published
through 2005, 518 (44.5%) pertain to pharmaceuticals. The
proportion of all CUAs that focus on pharmaceuticals increased
from 32% prior to 1990 to 48% from 1990–2005. U.S.-based
investigators account for 53.6% of the total (47.5% of pharma-
ceutical studies), though the relative proportion of US-based
studies has decreased over time. The U.K.’s share of total pub-
lished CUAs increased from 7% in 1990 to 18% in 2005. The
quality of study (as measured by a subjective 1–7 scale) did not
differ by type of sponsorship (4.4 for industry vs. 4.55 for non-
industry, p = 0.44). The leading journals for publishing pharma-
ceutical CUAs were Pharmacoeconomics (58 CUAs), Ann Intern
Med (47), Int J Technol Assess Health Care (37), JAMA (34) and
Am J Med (25). About 38% of pharmaceutical CUAs were
sponsored by pharmaceutical companies, 27% by non-industry
sources (and in 35% the source of funding could not be deter-
mined). Pﬁzer (26), Norvatis (25), Schering Plough (23), GSK
(21) and Roche (19) have funded the most pharmaceutical CUAs.
The median of 1055 pharmaceutical CE ratios is $26,000/QALY
and is lower for industry vs. non-industry funded studies
(p = 0.004). In multivariate analysis adjusting for factors such as
sponsor type, pharmaceutical CE ratios are similar to others—
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odds ratio for exceeding the overall median was 1.0 (95% CI:
0.64–1.55). CONCLUSION: Pharmaceutical CUAs account for
almost half of all published CUAs. The quality of studies does
not appear to differ according to study sponsor. In the published
literature, the cost-effectiveness of pharmaceuticals is similar to
that of other interventions.
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It has been 40 years (1968) since Herbert Klarman and col-
leagues published their paper in Medical Care establishing that
the cost-effectiveness of kidney dialysis is $50,000/QALY. This
served as the basis for expanding the United States Medicare
program to provide universal coverage for end stage renal disease
and subsequently the basis upon which all new health technology
has been compared. This standard has not changed throughout
the health technology assessment community despite years of
inﬂation and structural changes in health care systems since this
time. This paper will ﬁrst re-examine Klarman’s work and
show how he quality-adjusted the life years in the wrong
direction—producing ill-year rather than healthy-year equivalent
years; therefore, he grossly underestimates the cost-effectiveness
ratio associated with kidney dialysis. The implication of this
mistake for health technology assessment and some suggestions
for new CE threshold standards will be discussed. Current con-
ditions in health technology assessment require that these new
standards be both dynamic—allowing for change over time—and
ﬂexible to allow adjustment based on mitigating factors like
budget impact. Several examples and evidence from Australia,
the UK and the United States will be presented to indicate how
these standards might be developed.
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OBJECTIVE: Quantify effect of alternative econometric models,
in estimating total direct medical expenditure in diabetes, arthri-
tis, cardiac diseases, asthma, hypertension, stroke, and emphy-
sema. METHODS: Data from the MEPS’s Household
Component (2004), a nationally representative survey of the U.S.
civilian noninstitutionalized population, was used. Accounting
for the survey’s clusters, strata and sampling weights; total direct
medical expenditure was estimated under 11 different economet-
ric models to assess their sensitivity to the zero mass, non-
negative values and skewed distribution. Models compared were,
OLS on raw-expenditure (OLSraw); OLS on log-expenditure
(LnHom) and homoskedastic-retransformation; OLS on log-
expenditure (LnHet) and heteroskedastic-retransformation;
GLM with log-link and Gamma-family (GLMGam); GLM with
log-link and Poisson-family (GLMPoi); Extended Estimating
Equations (EEE); and 2-part models of OLSraw (2POLSraw);
LnHom (2PLnHom); LnHet (2PLnHet); GLMGam
(2PGLMGam); and GLMPoi (2PGLMPoi). Incremental expen-
diture from the method of recycled predictions summed over
diseased population gave total expenditure. Box-Cox test con-
ﬁrmed log-link for GLM models while Modiﬁed Park’s test deter-
mined a distribution between the Poisson and the Gamma for the
family. LINK, RESET and Hosmer-Lemeshow test determined
model ﬁt, while COPAS test was employed for over-ﬁtting and
cross validation. Covariates included age, gender, race, ethnicity,
marital status, education, insurance status, and comorbidity.
RESULTS: Total expenditure in billions (b) of dollars, for diabe-
tes ranged from $48.5b(2POLSraw) to $127b(LnHet). Similarly,
expenditure of arthritis ranged from $73b(2POLSraw) to
$196b(LnHet); cardiac diseases ranged from $99.2b(2POLSraw)
to $194b(LnHet); asthma ranged from $27.8b(2POLSraw) to
$64.2b(GLMGam); emphysema ranged from $2.1b(2PLnHom)
to $18.4b(LnHet); hypertension ranged from
$69.9b(2POLSraw) to $241b(LnHet) and stroke ranged from
$13.1b(2PLnHom) to $39.3b(LnHet). LnHet model was consis-
tently associated with the highest total expenditure estimate,
while 2POLSraw model typically predicted the lowest estimate.
CONCLUSION: The strong inﬂuence of model choice on the
total medical expenditure estimate, underscores importance of
understanding the data generation procedure before selection of
the appropriate estimator.
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OBJECTIVES: A disease’s workplace impact on an employer is
often highly sought but rarely available information that an
employer can use to understand the value of a health intervention
and to inﬂuence health insurance coverage of that intervention.
This document presents a conceptual framework to analyze a
disease’s workplace impact on an employer. METHODS: The
conceptual framework presented here was developed on the basis
of a comprehensive literature review, extensive consultation
process, analytical mapping of concepts, objects, behaviors,
domains, functions, and relationships, as well as real case analy-
ses. RESULTS: A four-component conceptual framework of
workplace impact of a disease is proposed to guide researchers to
quantify disease-workplace-impact from an employer perspec-
tive. These four components are work interruption costs, work
care costs, worker turnover costs and productivity reduction
costs. The examples of work interruption costs include employer-
paid medical leaves, absence, short-term disability, and other
forms of work interruption resulted from a disease. The
examples of work care costs include disease related work adap-
tation costs, and a disease related insurance premium increase.
The examples of worker turnover costs include worker separa-
tion costs, new worker recruitment costs, and new worker train-
ing costs. The productivity reduction costs are mainly the costs of
productivity decrease resulted from presenteeism. Both predis-
posing factors and intervening factors of workplace impact are
discussed in this conceptual framework. Based on this conceptual
framework, we conducted a real world case analysis, which
suggests not only signiﬁcant workplace impact of a debilitating
disease, but also some methodological challenges in estimating
workplace impact of a disease from an employer’s perspective.
CONCLUSIONS: Our four-component conceptual framework
can guide researchers to quantify workplace impact of a disease
from an employer’s perspective. The real case analysis suggests a
debilitating disease not only affect patients, but also exert signiﬁ-
cant workplace impact on an employer.
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